93 related articles for article (PubMed ID: 9479219)
1. [Derivatives of camptothecin. A new class of antineoplastic agents].
Astoul C; Ollitrault N; Salvat D
Soins; 1997 Dec; (621):37-40. PubMed ID: 9479219
[No Abstract] [Full Text] [Related]
2. [Development of cancer chemotherapy. Discovery of new active drugs. IV].
Lopez M
Clin Ter; 1999; 150(3):241-9. PubMed ID: 10528439
[No Abstract] [Full Text] [Related]
3. [Ovarian cancer. The new chemotherapeutic agents].
Catimel G; Talon A
Soins; 1995 Oct; (599):20-2, 24-5. PubMed ID: 8701349
[No Abstract] [Full Text] [Related]
4. Phase II study of intravenous DX-8951f in patients with advanced ovarian, tubal, or peritoneal cancer refractory to platinum, taxane, and topotecan.
Verschraegen CF; Levenback C; Vincent M; Wolf J; Bevers M; Loyer E; Kudelka AP; Kavanagh JJ
Ann N Y Acad Sci; 2000; 922():349-51. PubMed ID: 11193920
[No Abstract] [Full Text] [Related]
5. [Current status of camptothecin derivatives as natural antitumor agents].
Pan XD; Wang CY
Yao Xue Xue Bao; 2003 Sep; 38(9):715-20. PubMed ID: 14730926
[No Abstract] [Full Text] [Related]
6. Irinotecan for colorectal cancer: a small step forward.
O'Connell MJ
Lancet; 1998 Oct; 352(9138):1402. PubMed ID: 9807982
[No Abstract] [Full Text] [Related]
7. Irinotecan for metastatic colorectal cancer.
Med Lett Drugs Ther; 1997 Jan; 39(992):8. PubMed ID: 9008684
[No Abstract] [Full Text] [Related]
8. Whither irinotecan?
Blanke CD
J Clin Oncol; 2005 Aug; 23(22):4811-4. PubMed ID: 15939928
[No Abstract] [Full Text] [Related]
9. Irinotecan may extend survival in people with metastatic colorectal cancer.
Oncology (Williston Park); 1998 Oct; 12(10):1512. PubMed ID: 9798204
[No Abstract] [Full Text] [Related]
10. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
ten Bokkel Huinink W; Carmichael J; Armstrong D; Gordon A; Malfetano J
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
[TBL] [Abstract][Full Text] [Related]
11. [Irinotecan in the second-line therapy of metastatic colorectal carcinoma].
Petrasch S; Dörr T; Kemmeries G
Z Gastroenterol; 1999 Jun; 37(6):575-7. PubMed ID: 10427662
[No Abstract] [Full Text] [Related]
12. New options for the treatment of advanced ovarian cancer.
Dunton CJ
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-2-S5-11. PubMed ID: 9122739
[TBL] [Abstract][Full Text] [Related]
13. DNA topoisomerase I-targeting drugs as radiation sensitizers.
Chen AY; Choy H; Rothenberg ML
Oncology (Williston Park); 1999 Oct; 13(10 Suppl 5):39-46. PubMed ID: 10550825
[TBL] [Abstract][Full Text] [Related]
14. [New drugs. Topoisomerase inhibitors].
Gutzler F
Zentralbl Gynakol; 1996; 118(10):579. PubMed ID: 8999716
[No Abstract] [Full Text] [Related]
15. Topoisomerase I inhibitors: topotecan and irinotecan.
Jones SF; Burris HA
Cancer Pract; 1996; 4(1):51-3. PubMed ID: 8788772
[No Abstract] [Full Text] [Related]
16. Irinotecan and other agents in upper gastrointestinal and colorectal carcinomas. The University of Texas M. D. Anderson Cancer Center Investigators' Workshop, Volume 3. Introduction.
Ajani JA
Oncology (Williston Park); 2003 Sep; 17(9 Suppl 8):10-2. PubMed ID: 14569840
[No Abstract] [Full Text] [Related]
17. Topotecan: an important new drug in the management of ovarian cancer.
Markman M
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-1. PubMed ID: 9122736
[No Abstract] [Full Text] [Related]
18. Topotecan hydrochloride for metastatic ovarian cancer.
Med Lett Drugs Ther; 1996 Oct; 38(986):96-7. PubMed ID: 8906133
[No Abstract] [Full Text] [Related]
19. Nothing succeeds like failure.
Nat Biotechnol; 2002 Feb; 20(2):101. PubMed ID: 11821837
[No Abstract] [Full Text] [Related]
20. Camptothecins: new enthusiasm for an old drug.
Rowe PM
Lancet; 1996 Mar; 347(9005):892. PubMed ID: 8622402
[No Abstract] [Full Text] [Related]
[Next] [New Search]
